NASDAQ:COLL - Collegium Pharmaceutical Stock Price, Price Target & More

Get Started

$24.95 -0.07 (-0.28 %)

(As of 05/25/2018 09:09 AM ET)

Previous Close$25.02

Today's Range$24.40 - $25.1390

52-Week Range$8.01 - $29.90

Volume184,128 shs

Average Volume413,740 shs

Market Capitalization$826.76 million

P/E Ratio-10.10

Dividend YieldN/A

Beta0.78

About Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving. The company offers Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. It is also developing Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older. In addition, the company offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. Further, it is developing COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for attention deficit hyperactivity disorder (ADHD), as well as COL-196, a morphine formulation. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.

Receive COLL News and Ratings via Email

Sign-up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:COLL

CUSIPN/A

Webwww.collegiumpharma.com

Phone781-713-3699

Debt

Debt-to-Equity Ratio3.91

Current Ratio0.83

Quick Ratio0.80

Price-To-Earnings

Trailing P/E Ratio-10.10

Forward P/E Ratio-20.28

P/E GrowthN/A

Sales & Book Value

Annual Sales$28.48 million

Price / Sales28.94

Cash FlowN/A

Price / CashN/A

Book Value$2.75 per share

Price / Book9.07

Profitability

EPS (Most Recent Fiscal Year)($2.47)

Net Income$-74,860,000.00

Net Margins-78.22%

Return on Equity-72.87%

Return on Assets-26.11%

Miscellaneous

Employees250

Outstanding Shares33,040,000

Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical Inc (NASDAQ:COLL) issued its earnings results on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.02. The specialty pharmaceutical company earned $63.70 million during the quarter, compared to analyst estimates of $51.92 million. Collegium Pharmaceutical had a negative return on equity of 72.87% and a negative net margin of 78.22%. The business's revenue was up 2835.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.79) earnings per share. View Collegium Pharmaceutical's Earnings History.

What price target have analysts set for COLL?

6 Wall Street analysts have issued 12 month price objectives for Collegium Pharmaceutical's stock. Their predictions range from $26.00 to $35.00. On average, they expect Collegium Pharmaceutical's stock price to reach $31.80 in the next twelve months. View Analyst Ratings for Collegium Pharmaceutical.

Who are some of Collegium Pharmaceutical's key competitors?

Some companies that are related to Collegium Pharmaceutical include Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Tesaro (TSRO), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Emergent Biosolutions (EBS), Clovis Oncology (CLVS), Horizon Pharma (HZNP), Evotec A.G. (EVTCY), Global Blood Therapeutics (GBT), The Medicines (MDCO), Arena Pharmaceuticals (ARNA) and Heron Therapeutics (HRTX).

Who are Collegium Pharmaceutical's key executives?

Collegium Pharmaceutical's management team includes the folowing people:

Mr. Michael T. Heffernan, Founder, Chairman, Pres & CEO (Age 54)
Mr. Paul J. Brannelly, Exec. VP & CFO (Age 45)
Mr. Joseph J. Ciaffoni, Exec. VP & COO (Age 47)
Dr. Alison B. Fleming, Exec. VP & Chief Technology Officer (Age 43)
Ms. Shirley R. Kuhlmann, Exec. VP, Gen. Counsel & Sec. (Age 34)

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Has Collegium Pharmaceutical been receiving favorable news coverage?

Press coverage about COLL stock has been trending positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Collegium Pharmaceutical earned a coverage optimism score of 0.28 on Accern's scale. They also assigned media coverage about the specialty pharmaceutical company an impact score of 45.24 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Collegium Pharmaceutical's major shareholders?

Collegium Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.99%), Rock Springs Capital Management LP (5.81%), Franklin Resources Inc. (4.45%), Massachusetts Financial Services Co. MA (1.25%), Prudential Financial Inc. (1.05%) and Summit Trail Advisors LLC (1.01%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, John A Fallon, Longitude Capital Partners, Ll, Michael Thomas Heffernan and Paul Brannelly. View Institutional Ownership Trends for Collegium Pharmaceutical.

Which institutional investors are selling Collegium Pharmaceutical stock?

COLL stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Prudential Financial Inc., Wells Fargo & Company MN, Granite Investment Partners LLC, Franklin Resources Inc., Millennium Management LLC, Cortina Asset Management LLC and Massachusetts Financial Services Co. MA. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include Alison B Fleming, Longitude Capital Partners, Ll and Michael Thomas Heffernan. View Insider Buying and Selling for Collegium Pharmaceutical.

Which institutional investors are buying Collegium Pharmaceutical stock?

COLL stock was purchased by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Osterweis Capital Management Inc., Russell Investments Group Ltd., Tygh Capital Management Inc., Timpani Capital Management LLC, Fisher Asset Management LLC, UBS Group AG and JPMorgan Chase & Co.. Company insiders that have bought Collegium Pharmaceutical stock in the last two years include John A Fallon and Paul Brannelly. View Insider Buying and Selling for Collegium Pharmaceutical.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $24.95.

How big of a company is Collegium Pharmaceutical?

Collegium Pharmaceutical has a market capitalization of $826.76 million and generates $28.48 million in revenue each year. The specialty pharmaceutical company earns $-74,860,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Collegium Pharmaceutical employs 250 workers across the globe.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 780 DEDHAM STREET SUITE 800, CANTON MA, 02021. The specialty pharmaceutical company can be reached via phone at 781-713-3699.

MarketBeat Community Rating for Collegium Pharmaceutical (COLL)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		173 (Vote Outperform)
Underperform Votes:		186 (Vote Underperform)
Total Votes:		359

MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote "Outperform" if you believe COLL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COLL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Collegium Pharmaceutical (NASDAQ:COLL) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

6 Wall Street analysts have issued ratings and price targets for Collegium Pharmaceutical in the last 12 months. Their average twelve-month price target is $31.80, suggesting that the stock has a possible upside of 27.45%. The high price target for COLL is $35.00 and the low price target for COLL is $26.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$31.80	$31.80	$29.40	$20.00
Price Target Upside:	27.45% upside	33.84% upside	35.05% upside	18.91% upside

Collegium Pharmaceutical (NASDAQ:COLL) Consensus Price Target History

Price Target History for Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ:COLL) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/8/2018	William Blair	Reiterated Rating	Outperform		High
3/8/2018	HC Wainwright	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $33.00	High
2/12/2018	Jefferies Group	Boost Price Target	Buy	$32.00	Low
2/12/2018	Piper Jaffray Companies	Set Price Target	Buy	$33.00	High
2/7/2018	Needham & Company LLC	Boost Price Target	Buy ➝ Buy	$28.00 ➝ $35.00	Low
2/6/2018	Janney Montgomery Scott	Set Price Target	Buy ➝ Buy	$21.00 ➝ $26.00	Low
9/13/2016	Gabelli	Initiated Coverage	Buy	$25.00	N/A

(Data available from 5/25/2016 forward)

Collegium Pharmaceutical (NASDAQ:COLL) Earnings History and Estimates Chart

Earnings by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ:COLL) Earnings Estimates

2018 EPS Consensus Estimate: ($0.77)
2019 EPS Consensus Estimate: $0.46

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	($0.73)	($0.23)	($0.48)
Q2 2018	3	($0.31)	($0.12)	($0.22)
Q3 2018	3	($0.18)	($0.05)	($0.09)
Q4 2018	3	($0.05)	$0.15	$0.02
Q1 2019	1	($0.13)	($0.13)	($0.13)
Q2 2019	1	$0.13	$0.13	$0.13
Q3 2019	1	$0.21	$0.21	$0.21
Q4 2019	1	$0.25	$0.25	$0.25

Collegium Pharmaceutical (NASDAQ COLL) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/9/2018	Q1 2018	($0.55)	($0.57)	$51.92 million	$63.70 million	View	N/A
3/7/2018	Q4 2017	($0.56)	($0.54)	$9.88 million	$10.79 million	View	Listen
11/8/2017	Q3 2017	($0.73)	($0.45)	$5.31 million	$11.95 million	View	N/A
8/9/2017	Q2 2017	($0.81)	($0.72)	$4.07 million	$3.56 million	View	Listen
5/10/2017	Q1 2017	($0.9760)	($0.79)	$3.55 million	$2.17 million	View	N/A
3/9/2017	Q4 2016	($1.07)	($1.02)	$1.79 million	$1.30 million	View	Listen
11/10/2016	Q3 2016	($1.09)	($1.13)	$1.00 million	$0.41 million	View	Listen
8/10/2016	Q2	($0.7580)	($1.05)	$0.16 million		View	Listen
5/10/2016	Q1	($0.60)	($0.68)			View	Listen
3/15/2016	Q415	($0.45)	($0.46)			View	Listen
11/12/2015	Q315	($0.30)	($0.46)			View	Listen
8/12/2015	Q215	($0.26)	($0.45)			View	Listen

(Earnings results data provided by Zacks Investment Research)

Collegium Pharmaceutical (NASDAQ:COLL) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Collegium Pharmaceutical (NASDAQ COLL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 25.76%
Institutional Ownership Percentage: 92.51%

Insider Trading History for Collegium Pharmaceutical (NASDAQ:COLL)

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ COLL) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/19/2018	Michael Thomas Heffernan	Chairman	Sell	44,400	$26.00	$1,154,400.00	545,893
1/23/2018	Michael Thomas Heffernan	Chairman	Sell	20,000	$25.01	$500,200.00	535,395
1/19/2018	Michael Thomas Heffernan	Chairman	Sell	20,000	$22.50	$450,000.00	538,987
1/10/2018	Alison B Fleming	Insider	Sell	6,928	$19.07	$132,116.96	32,651
12/8/2017	Longitude Capital Partners, Ll	Major Shareholder	Sell	1,000,000	$17.34	$17,340,000.00
11/21/2017	Alison B Fleming	Insider	Sell	4,601	$17.25	$79,367.25	28,513
11/17/2017	Alison B Fleming	CTO	Sell	4,029	$17.00	$68,493.00	28,513
11/15/2017	Michael Thomas Heffernan	CEO	Sell	50,000	$15.53	$776,500.00	558,987
5/12/2017	Paul Brannelly	Insider	Buy	10,000	$9.18	$91,800.00	110,227
8/12/2016	John A Fallon	Director	Buy	2,375	$10.59	$25,151.25	2,375
5/12/2015	John Gordon Freund	Director	Buy	150,000	$12.00	$1,800,000.00
5/12/2015	Longitude Capital Partners, Ll	Major Shareholder	Buy	200,000	$12.00	$2,400,000.00

(Data available from 1/1/2013 forward)

Collegium Pharmaceutical (NASDAQ COLL) News Headlines

Source:

Date	Headline
	Brokerages Expect Collegium Pharmaceutical (COLL) Will Announce Quarterly Sales of $72.39 Million www.americanbankingnews.com - May 16 at 4:28 AM
	Collegium Pharmaceutical (COLL) Downgraded by Zacks Investment Research to "Hold" www.americanbankingnews.com - May 15 at 8:15 PM
	BidaskClub Upgrades Collegium Pharmaceutical (COLL) to "Buy" www.americanbankingnews.com - May 15 at 1:31 PM
	Jefferies Group Analysts Boost Earnings Estimates for Collegium Pharmaceutical (COLL) www.americanbankingnews.com - May 14 at 5:05 AM
	Analysts Expect Collegium Pharmaceutical (COLL) to Post -$0.19 EPS www.americanbankingnews.com - May 14 at 3:27 AM
	Q2 2018 EPS Estimates for Collegium Pharmaceutical (COLL) Reduced by Analyst www.americanbankingnews.com - May 14 at 2:37 AM
	FY2021 Earnings Forecast for Collegium Pharmaceutical (COLL) Issued By Piper Jaffray www.americanbankingnews.com - May 11 at 11:47 AM
	Depomed Announces First-Quarter 2018 Financial Results finance.yahoo.com - May 10 at 8:41 AM
	Kala Pharmaceuticals Strengthens Commercial Organization in Preparation for First Product Launch www.bizjournals.com - May 10 at 8:41 AM
	Collegium Pharmaceutical's (COLL) CEO Michael Heffernan on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 10 at 8:41 AM
	Edited Transcript of COLL earnings conference call or presentation 9-May-18 8:30pm GMT finance.yahoo.com - May 10 at 8:41 AM
	Collegium Pharmaceutical (COLL) Releases Earnings Results, Misses Expectations By $0.02 EPS www.americanbankingnews.com - May 10 at 12:14 AM
	Collegium Pharmaceutical misses by $0.08, beats on revenue seekingalpha.com - May 9 at 5:17 PM
	Collegium Pharmaceutical: 1Q Earnings Snapshot finance.yahoo.com - May 9 at 5:17 PM
	Collegium Reports First Quarter Financial Results and Provides Corporate Update finance.yahoo.com - May 9 at 5:17 PM
	Where Collegium Pharmaceutical Inc (NASDAQ:COLL) Stands In Earnings Growth Against Its Industry finance.yahoo.com - May 9 at 5:17 PM
	Collegium Pharmaceutical (COLL) Downgraded to D at TheStreet www.americanbankingnews.com - May 9 at 3:12 PM
	Collegium Pharmaceutical (COLL) Receives Average Recommendation of "Buy" from Brokerages www.americanbankingnews.com - May 3 at 5:32 AM
	Collegium to Present at the Deutsche Bank Health Care Conference finance.yahoo.com - May 2 at 5:14 PM
	Collegium Pharmaceutical (COLL) Scheduled to Post Quarterly Earnings on Wednesday www.americanbankingnews.com - May 2 at 7:08 AM
	Collegium Pharmaceutical (COLL) Expected to Announce Quarterly Sales of $49.64 Million www.americanbankingnews.com - April 28 at 2:48 AM
	Collegium Pharmaceutical (COLL) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 27 at 12:18 PM
	Analysts Anticipate Collegium Pharmaceutical (COLL) to Post -$0.68 Earnings Per Share www.americanbankingnews.com - April 26 at 3:10 PM
	Analysts Issue Forecasts for Collegium Pharmaceutical's FY2020 Earnings (COLL) www.americanbankingnews.com - April 25 at 9:38 AM
	Michael Thomas Heffernan Sells 44,400 Shares of Collegium Pharmaceutical (COLL) Stock www.americanbankingnews.com - April 23 at 7:10 PM
	Investor Expectations to Drive Momentum within WESCO International, Microchip ... globenewswire.com - April 23 at 9:06 AM
	Collegium Pharmaceutical (COLL) Upgraded at BidaskClub www.americanbankingnews.com - April 21 at 7:06 AM
	Collegium Pharmaceutical (COLL) to Post Q1 2018 Earnings of ($0.73) Per Share, William Blair Forecasts www.americanbankingnews.com - April 18 at 7:58 AM
	William Blair Comments on Collegium Pharmaceutical's FY2019 Earnings (COLL) www.americanbankingnews.com - April 17 at 7:05 AM
	Collegium Pharmaceutical (COLL) Upgraded by Zacks Investment Research to "Buy" www.americanbankingnews.com - April 16 at 8:40 PM
	Collegium Pharmaceutical, Inc. (COLL) Sees Hammer Chart Pattern: Time to Buy? finance.yahoo.com - April 16 at 9:16 AM
	Brokerages Anticipate Collegium Pharmaceutical (COLL) Will Announce Quarterly Sales of $49.73 Million www.americanbankingnews.com - April 11 at 2:23 AM
	-$0.69 EPS Expected for Collegium Pharmaceutical (COLL) This Quarter www.americanbankingnews.com - April 9 at 5:24 PM
	Collegium Pharmaceutical (COLL) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - April 8 at 5:11 AM
	Collegium Pharmaceutical (COLL) Downgraded by BidaskClub to "Hold" www.americanbankingnews.com - April 5 at 10:33 AM
	Collegium to Present at the H.C. Wainwright Global Life Sciences Conference finance.yahoo.com - April 4 at 4:36 PM
	Collegium Pharmaceutical (COLL) Upgraded by ValuEngine to "Buy" www.americanbankingnews.com - April 3 at 5:52 PM
	HC Wainwright Reaffirms Buy Rating for Collegium Pharmaceutical (COLL) www.americanbankingnews.com - April 1 at 10:34 AM
	Collegium Pharmaceutical (COLL) Downgraded by BidaskClub to Buy www.americanbankingnews.com - March 30 at 9:27 AM
	BidaskClub Upgrades Collegium Pharmaceutical (COLL) to Buy www.americanbankingnews.com - March 28 at 11:21 AM
	Piper Jaffray Analysts Give Collegium Pharmaceutical (COLL) a $33.00 Price Target www.americanbankingnews.com - March 26 at 9:18 PM
	$49.73 Million in Sales Expected for Collegium Pharmaceutical Inc (COLL) This Quarter www.americanbankingnews.com - March 25 at 2:54 AM
	Commit To Buy Collegium Pharmaceuticals At $17.50, Earn 14.9% Annualized Using Options - Nasdaq www.nasdaq.com - March 24 at 8:27 AM
	Notice to Convene Annual General Meeting 2018 finance.yahoo.com - March 23 at 8:33 AM
	Collegium Announces the Appointment of Shirley Kuhlmann as General Counsel - GlobeNewswire (press release) globenewswire.com - March 20 at 8:12 AM
	Collegium Announces the Appointment of Shirley Kuhlmann as General Counsel finance.yahoo.com - March 19 at 9:08 AM
	Collegium Pharmaceutical Inc (COLL) Given Average Recommendation of "Buy" by Brokerages www.americanbankingnews.com - March 14 at 5:36 AM
	Contrasting Collegium Pharmaceutical (COLL) & Corcept Therapeutics (CORT) www.americanbankingnews.com - March 14 at 1:26 AM
	Brokers Issue Forecasts for Collegium Pharmaceutical Inc's FY2019 Earnings (COLL) www.americanbankingnews.com - March 12 at 8:51 AM
	William Blair Analysts Increase Earnings Estimates for Collegium Pharmaceutical Inc (COLL) www.americanbankingnews.com - March 12 at 2:32 AM

Collegium Pharmaceutical (NASDAQ:COLL) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Collegium Pharmaceutical (NASDAQ:COLL) Income Statement, Balance Sheet and Cash Flow Statement

Collegium Pharmaceutical (NASDAQ COLL) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff